WO2000004918A3 - Mittel zur immuntherapie von tumorerkrankungen - Google Patents

Mittel zur immuntherapie von tumorerkrankungen Download PDF

Info

Publication number
WO2000004918A3
WO2000004918A3 PCT/DE1999/002280 DE9902280W WO0004918A3 WO 2000004918 A3 WO2000004918 A3 WO 2000004918A3 DE 9902280 W DE9902280 W DE 9902280W WO 0004918 A3 WO0004918 A3 WO 0004918A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
immunotherapy
tumour
tumoral diseases
cells
Prior art date
Application number
PCT/DE1999/002280
Other languages
English (en)
French (fr)
Other versions
WO2000004918A2 (de
Inventor
Aida Kerkmann-Tucek
Original Assignee
Kerkmann Tucek Aida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kerkmann Tucek Aida filed Critical Kerkmann Tucek Aida
Priority to AU61864/99A priority Critical patent/AU6186499A/en
Priority to EP99948682A priority patent/EP1098960A2/de
Publication of WO2000004918A2 publication Critical patent/WO2000004918A2/de
Publication of WO2000004918A3 publication Critical patent/WO2000004918A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft Mittel, die sich zur Immuntherapie von Tumorerkrankungen eignen. Solche Mittel sind Tumorzellen mit einer in einem Menschen vorliegenden Kombination von MHC I- und MHC II-Genen, wobei die Gene exprimiert werden, eine die Tumorzellen enthaltende Tumorzell-Bibliothek und die Tumorzellen umfassende Vakzine. Ferner betrifft die Erfindung ein Verfahren zur Herstellung der Tumorzellen und die Verwendung dieser sowie der Vakzine und der Tumorzell-Bibliothek.
PCT/DE1999/002280 1998-07-21 1999-07-21 Mittel zur immuntherapie von tumorerkrankungen WO2000004918A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU61864/99A AU6186499A (en) 1998-07-21 1999-07-21 Agents for the immunotherapy of tumoral diseases
EP99948682A EP1098960A2 (de) 1998-07-21 1999-07-21 Mittel zur immuntherapie von tumorerkrankungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19832840A DE19832840C1 (de) 1998-07-21 1998-07-21 Mittel zur Immuntherapie von Tumorerkrankungen
DE19832840.0 1998-07-21

Publications (2)

Publication Number Publication Date
WO2000004918A2 WO2000004918A2 (de) 2000-02-03
WO2000004918A3 true WO2000004918A3 (de) 2000-04-20

Family

ID=7874839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/002280 WO2000004918A2 (de) 1998-07-21 1999-07-21 Mittel zur immuntherapie von tumorerkrankungen

Country Status (4)

Country Link
EP (1) EP1098960A2 (de)
AU (1) AU6186499A (de)
DE (1) DE19832840C1 (de)
WO (1) WO2000004918A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272617B1 (de) 2000-04-01 2011-04-27 Onyvax Limited Prostata zellinien und deren verwendung
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
AU785241B2 (en) * 2000-05-17 2006-11-23 Cancure Limited Immune potentiating compositions
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
ATE512668T1 (de) 2003-12-30 2011-07-15 Mologen Ag Allogenes tumortherapeutikum
WO2007035836A2 (en) * 2005-09-20 2007-03-29 The Board Of Regents Of The University Of Oklahoma Accelerated class i and class ii hla dna sequence-based typing
WO2023167973A1 (en) * 2022-03-03 2023-09-07 Briacell Therapeutics Corp. Cancer vaccines and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569678A2 (de) * 1992-03-13 1993-11-18 Yeda Research And Development Co. Ltd. Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen
WO1997024132A1 (en) * 1995-12-28 1997-07-10 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569678A2 (de) * 1992-03-13 1993-11-18 Yeda Research And Development Co. Ltd. Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
WO1997024132A1 (en) * 1995-12-28 1997-07-10 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
I. FLORES ET AL.: "IFN-GAMMA AND B7 AS COSTIMULATORS OF ANTITUMOR IMMUNE RESPONSES.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 7, 1995, pages 501 - 509, XP000605140 *
M. LINDAUER ET AL.: "GENE TRANSFER OF COSTIMULATORY MOLECULES INTO A HUMAN COLORECTAL CANCER CELL LINE: REQUIREMENT OF CD54, CD80 AND CLASS II MHC EXPRESSION FOR ENHANCED IMMUNITY.", IMMUNOLOGY, vol. 93, no. 3, March 1998 (1998-03-01), OXFORD, GB, pages 390 - 397, XP000876810 *
S. OSTRAND-ROSENBERG: "TRANSFECTION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I AND CLASS II GENES CAUSES TUMOR REJECTION.", JOURNAL OF IMMUNOGENETICS, vol. 16, no. 4/5, 1989, OXFORD, GB, pages 343 - 349, XP000876764 *

Also Published As

Publication number Publication date
WO2000004918A2 (de) 2000-02-03
AU6186499A (en) 2000-02-14
DE19832840C1 (de) 2000-06-08
EP1098960A2 (de) 2001-05-16

Similar Documents

Publication Publication Date Title
AP2000001762A0 (en) Method of delivering genes to antigen presenting cells of the skin
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002058534A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000004918A3 (de) Mittel zur immuntherapie von tumorerkrankungen
WO2000029551A3 (en) Cells, culture methods, and their use in autologous transplantation therapy
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005017100A3 (en) Ribonucleases and methods of making them recombinantly
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999948682

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09744186

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999948682

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999948682

Country of ref document: EP